The document discusses how damage to the locus coeruleus (LC) in transgenic mouse models of Alzheimer's disease (AD) leads to reduced levels of norepinephrine (NA) in the central nervous system. It presents the hypothesis that increasing NA levels through treatment with L-DOPS, a norepinephrine prodrug, may provide benefits for transgenic AD mice with endogenous LC damage. The results showed that L-DOPS increased NA levels, reduced amyloid plaques, improved memory, and increased neurotrophin expression in the transgenic mice. LC damage and inflammation may also occur in multiple sclerosis and its rodent model.